Upgrade to SI Premium - Free Trial

Roche (RHHBY)

51.70 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Latest Headlines

UBS Reiterates Buy Rating on Roche Holding (ROG:SW) (RHHBY) July 23, 2026 3:14 AM - StreetInsider Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges July 22, 2026 9:00 AM - PR NewsWire Roche names new diagnostics North America chief, effective Aug. 1 July 20, 2026 8:20 AM - StreetInsider Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America July 20, 2026 8:20 AM - PR NewsWire FDA grants priority review to Genentech's Gazyva for kidney disease July 15, 2026 1:01 AM - StreetInsider FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy July 15, 2026 1:01 AM - BizWire Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC July 7, 2026 1:01 AM - BizWire HSBC Downgrades Roche Holding (ROG:SW) (RHHBY) to Hold July 6, 2026 1:32 AM - StreetInsider Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer July 2, 2026 1:10 AM - BizWire FDA grants priority review to Genentech's Enspryng for thyroid eye disease June 30, 2026 1:09 AM - StreetInsider FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED) June 30, 2026 1:09 AM - BizWire FDA accepts Genentech's application for Lunsumio and Polivy combo June 18, 2026 1:00 AM - StreetInsider FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma June 18, 2026 1:00 AM - BizWire FDA grants priority review for Genentech's Tecentriq in stage III colon cancer June 11, 2026 1:05 AM - StreetInsider FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer June 11, 2026 1:05 AM - BizWire Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies June 11, 2026 1:00 AM - PR NewsWire Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology June 8, 2026 1:00 AM - Globe NewsWire Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection June 4, 2026 11:34 AM - PR NewsWire U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer wit June 2, 2026 7:00 AM - BizWire FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting June 2, 2026 1:05 AM - BizWire Genentech to present obesity drug data at diabetes conference June 1, 2026 1:01 AM - StreetInsider Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions June 1, 2026 1:01 AM - BizWire Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026 May 21, 2026 5:00 PM - BizWire New Research Confirms Data Quality as the Defining Priority Across the Real-World Evidence Landscape May 20, 2026 9:00 AM - BizWire Flatiron Health Launches Flatiron Telescope, a New AI Platform Delivering Oncology Insights in Minutes May 19, 2026 9:00 AM - BizWire Genentech presents new giredestrant breast cancer data at ASCO 2026 May 19, 2026 1:05 AM - StreetInsider Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer May 19, 2026 1:05 AM - BizWire FDA approves Genentech's Tecentriq for bladder cancer with ctDNA guidance May 15, 2026 12:45 PM - StreetInsider FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment May 15, 2026 12:45 PM - BizWire Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026 April 30, 2026 1:00 AM - BizWire Roche Holding (ROG:SW) (RHHBY) PT Lowered to CHF376 at UBS April 27, 2026 4:43 AM - StreetInsider Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign April 24, 2026 8:00 AM - BizWire Morgan Stanley Upgrades Roche Holding (ROG:SW) (RHHBY) to Equalweight April 24, 2026 2:49 AM - StreetInsider Morgan Stanley Upgrades Roche (RHHBY) to Equalweight April 24, 2026 2:47 AM - StreetInsider Full Article List